Press release
Marinomed Biotech AG, listed on the Vienna Stock Exchange (VSE:MARI), today announced positive results from its clinical study on the decongestant effect of the Sorbitol-containing Carragelose nasal spray. The double-blind, two-way cross-over, randomized and placebo-controlled study was conducted at the Vienna Challenge Chamber. While Carragelose was shown to be an effective treatment of viral infections of the respiratory tract, Sorbitol exerts a decongestant effect. Therefore, the product is indicated for the supportive treatment of rhinitis of any kind with the symptom of a blocked nose. Using the product as a treatment against allergies may help to both relieve the allergy symptoms and to reduce the risk of a viral respiratory infection. The latter is particularly important because respiratory viral infections may cause a worsening of the underlying allergic disorder in these patients. The Carragelose and Sorbitol nasal spray was launched in 2018 and is currently marketed in 11 countries as a common cold product. Based on the current clinical results, Marinomed plans to expand both the applications and target markets for the decongestant nasal spray.
The full press release is available as download here: